E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with Invasive Pulmonary Aspergillosis |
|
E.1.1.1 | Medical condition in easily understood language |
Infection caused by Aspergillus, a common mold (a type of fungus) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Bacterial Infections and Mycoses [C01] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10059259 |
E.1.2 | Term | Pulmonary aspergillosis |
E.1.2 | System Organ Class | 100000004862 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the safety and tolerability of the coadministration of SCY-078 and voriconazole compared with the coadministration of SCY-078 placebo and voriconazole in the treatment of invasive pulmonary aspergillosis (IPA). |
|
E.2.2 | Secondary objectives of the trial |
• To evaluate the efficacy of the coadministration of SCY-078 and voriconazole compared with that of SCY-078 placebo and voriconazole in the treatment of IPA o based on Global Response as determined by the Data Review Committee (DRC) as determined by the Principal Investigator o based on all-cause mortality (ACM) o based on serum galactomannan index (GMI) decrease o based on clinical response, mycological response and radiological response as determined by the DRC as determined by the Principal Investigator • To evaluate the pharmacokinetics (PK) of SCY-078 and voriconazole |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Subject is a male or female adult ≥18 years of age on the day the study informed consent form (ICF) is signed. 2. Subject has a probable or proven IPA based on the protocol-specified criteria (Section 22.3) that requires antifungal treatment. Note: Subjects with possible IPA may enter the screening phase of the study but will only be randomized after meeting criteria for probable or proven IPA
3. Subject has a result of a serum GMI from a sample obtained within the 96 hours preceding enrollment into the study (Baseline/Treatment Day 1). 4. Subject has one of the following: a. a diagnosis of a hematological malignancy or a myelodysplastic syndrome or aplastic anemia or has undergone hematopoietic cell transplantation, OR b. who either recently resolved or ongoing neutropenia (neutropenia defined as absolute neutrophil count < 0.5 x 109/L [< 500/mm3] for > 10 days), temporally related to the onset of fungal disease OR c. who received treatment with other recognized T-cell immunosuppressants (such as cyclosporine, tacrolimus, monoclonal antibodies or nucleoside analogs) during the past 90 days including solid organ transplant patients OR d. with inherited severe immunodeficiency (e.g. chronic granulomatous disease, severe combined immunodeficiency). 5. Subject has not received more than 4 days (96 hours) of prior mold-active antifungal 12 NOV 2018 CONFIDENTIAL Page 22 therapy for the treatment of the IPA episode in the 7 days preceding enrollment into the study (Baseline/Treatment Day 1). However, subjects who have received more than 4 days but less than 7 days of prior mold-active antifungal therapy for the treatment of the IPA episode in the 7 days preceding enrollment into the study may be enrolled but will require approval from the study medical monitor, who will evaluate each subject on a case-by-case basis. 6.For subjects who were receiving antifungal prophylaxis, the IPA episode would, in the investigator´s judgement, be adequately treated with voriconazole . 7. Subject is able to tolerate medication orally or through a nasogastric (NG) tube or percutaneous endoscopic gastrostomy (PEG) tube. 8. Subject is not pregnant and is highly unlikely to become pregnant or to impregnate a partner since he/she meets at least one of the following criteria: a. Subject is a female subject who is not of reproductive potential and is eligible without requiring the use of contraception. A female subject who is not of reproductive potential is defined as one who: (1) has reached natural menopause (defined as 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone levels in the postmenopausal range as determined by the local laboratory, or 12 months of spontaneous amenorrhea); (2) is 6 weeks´ post-surgical bilateral oophorectomy or hysterectomy; or (3) has undergone bilateral tubal ligation. Spontaneous amenorrhea does not include cases for which there is an underlying disease that causes amenorrhea (i.e., anorexia nervosa). b. Subject is a male subject who is not of reproductive potential and is eligible without requiring the use of contraception. A male subject who is not of reproductive potential is defined as one whom has undergone a successful vasectomy. A successful vasectomy is defined as (1) microscopic documentation of azoospermia, or (2) a vasectomy more than 2 years ago with no resultant pregnancy despite sexual activity post vasectomy. c. Subject is a male or female subject who is of reproductive potential, is not pregnant or nursing, and agrees to remain abstinent or use (or have his/her partner use) 2 acceptable methods of contraception starting from the time of consent through 28 days after the completion of study therapy. Acceptable methods of birth control are intrauterine device, condom and highly effective hormonal contraceptives. Note: Participating females of childbearing potential must have a negative urine or serum pregnancy test (β-human chorionic gonadotropin [β-hCG]) at Screening and prior to enrollment (Baseline/Treatment Day 1) (performed by the site’s local laboratory). 9. Subject and/or legal representative is/are able to understand and sign a written ICF, which must be obtained prior to treatment and any study-related procedures. 10. Subject and/or legal representative is able to understand and sign a consent or authorization form, which shall permit the use, disclosure and transfer of the subject’s personal health information (e.g., in the US, a Health Information Portability and Accountability Act Authorization form). 11. Subject and/or legal representative is able to understand and follow all study-related procedures including study drug administration. 12. Subject is willing and able to comply with the study restrictions and participate for the full length of the study. |
|
E.4 | Principal exclusion criteria |
1. Subject has a fungal disease with central nervous system involvement suspected at Screening. 2. Subject is receiving, has received or anticipates to be receiving concomitant medications that are listed in the prohibited medication list (Appendix A in full protocol) within the specified washout periods. 3. Subject has a Karnofsky score <20. 4. Subject is expected to die from a non-infectious cause within 30 days from the day the study ICF is signed. 5. Subject is under mechanical ventilation. 6. Subject has abnormal liver test parameters: AST or ALT >10 x ULN and/or total bilirubin >5 x ULN. Note: Subjects with unconjugated hyperbilirubinemia ( <7 mg/dL ) with a diagnosis of Gilbert’s disease are not excluded. 7. Subject has a grade II-IV acute or extensive chronic graft-versus-host disease (GvHD). 8. Subject has renal failure requiring dialysis. 9. Subject has a prolonged QTcF interval (Fridericia’s correction: QTc= QT/(RR)0.33) >480 ms for females and prolonged QTcF interval (Fridericia’s correction: QTc= QT/(RR)0.33) >450 ms for males, on the baseline ECG or other abnormalities deemed clinically significant by the investigator that would put the subject at unacceptable risk for participation in the study. 10. Subject has any other condition including history of conditions or medications that may increase the risk for QTc prolongation, or laboratory abnormality that, in the judgment of the investigator, would put the subject at unacceptable risk for participation in the study or may interfere with the assessments included in the study. 11. Subject has a known hypersensitivity to SCY-078 and/or voriconazole or any of the components of the formulations. 12. Subject has participated in any other investigational study (except open-label studies including approved chemotherapy agents) within at least 28 days or 5.5 half-lives of the investigational product (whichever is longer) before signing the ICF. 13. Subject has received prior treatment with SCY-078 in a previous trial. 14. Subject is an employee of SCYNEXIS, Inc., the investigator or the Contract Research Organization (CRO) involved in the study, or is an immediate family member (partner, offspring, parent, sibling, or sibling’s offspring) of an employee involved in the study. 15. Subject is unlikely to comply with protocol requirements. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Frequency of treatment-emergent adverse events (TEAEs), drug-related adverse events (AEs), discontinuations due to AEs and deaths. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
• Global Response as measured by: o Percentage of subjects with Complete Response or Partial Response at EoT (key secondary endpoint), Day 42 and Day 84, as determined by the DRC o Percentage of subjects with Complete Response or Partial Response at EoT, Day 42 and Day 84, as determined by the Principal Investigator • Overall survival, defined as the time from randomization to time of death up to Day 84 • Percentage of subjects who died (any cause) at Days 42 and 84 • Absolute reduction and percent change in serum GMI from Baseline to Weeks 1, 2, 4 and 6 • Percentage of subjects with the following changes in serum GMI from Baseline: o Fifty percent reduction or greater at Weeks 1, 2, 4 and 6 o Twenty-five percent reduction or greater at Weeks 1, 2, 4 and 6 o Any percent reduction at Weeks 1, 2, 4 and 6 o Reduction equal to or greater than 0.25 at Weeks 1, 2, 4 and 6 o Reduction to < 0.5 at Weeks 1, 2, 4 and 6 • Time to achieve the following changes in serum GMI from Baseline: o Fifty percent reduction o Twenty-five percent reduction o Any percent reduction o Reduction equal to or greater than 0.25 o Reduction to < 0.5 in 2 consecutive samples • Percentage of subjects with: o Clinical Response at EoT, Day 42 and Day 84, as determined by the DRC o Mycological Response at EoT, Day 42 and Day 84, as determined by the DRC o Radiological Response at EoT, Day 42 and Day 84, as determined by the DRC • Percentage of subjects with: o Clinical Response at EoT, Day 42 and Day 84, as determined by the Principal Investigator o Mycological Response at EoT, Day 42 and Day 84, as determined by the Principal Investigator o Radiological Response at EoT, Day 42 and Day 84, as determined by the Principal Investigator • SCY-078 and voriconazole plasma concentrations population PK analysis |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Timepoint is included in the relevant endpoint |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | Yes |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 20 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
United States |
Belgium |
Germany |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 3 |